Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Clinical trial NCT00615186 · TERMINATED
Trial details
- NCT number
- NCT00615186
- Sponsor
- Bradmer Pharmaceuticals Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-06-01
- Primary completion
- 2013-08-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.